Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJELIOT: Prexasertib in Pediatric Medulloblastoma
NCT04023669Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prexasertib in medulloblastoma (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 month, Safety and Tolerability up to 2 years and 2 more. Started Aug 2019; status: completed.
02
Drugs
prexasertib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04023669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023669.